Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Alabama at Birmingham

Sites in Birmingham, AL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1240
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Alabama at Birmingham, Birmingham, AL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Alabama at Birmingham, Birmingham, AL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 445–456 of 1,240 matching trials with a site at University of Alabama at Birmingham, Birmingham, AL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1Phase 2 Interventional Results available

Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

NCT05471843
Site status not listed — check the official record
View directory record Official record
Conditions
Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
Interventions
Sonrotoclax
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Fort Wayne, Indiana • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 29, 2026, 1:50 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers Results available

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

NCT02003222
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Leucovorin Calcium, Lumbar Puncture, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
30 Years to 70 Years
Enrollment
488 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
531
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 1:50 AM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin for Methamphetamine Use Disorder

NCT07774702
Site status not listed — check the official record
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Psilocybin (single oral capsule administered at one of two dose levels, Dose A or Dose B; specific doses withheld during conduct)., Manualized cognitive behavioral therapy platform (2 preparation + 2 integration sessions).
Drug · Behavioral
Lead sponsor
Peter Hendricks
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 1:50 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

NCT04586010
Site status not listed — check the official record
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Fenebrutinib, Teriflunomide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 1:50 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

NCT07161037
Site status not listed — check the official record
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
26
States / cities
Alabaster, Alabama • Birmingham, Alabama • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 1:50 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

NCT02620852
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer Screening, Breast Carcinoma in Situ, Breast Cancer
Interventions
Complete a health questionnaire, Provide a saliva sample for genetic testing, Screening advice based on a comprehensive risk assessment, Screening advice based on a basic risk assessment
Other · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years to 74 Years · Female only
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2029
U.S. locations
11
States / cities
Birmingham, Alabama • Irvine, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 1:50 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Integrating Supports to Promote PrEP for Black Adolescents Working With Apps- Alabama

NCT06876324
Site status not listed — check the official record
View directory record Official record
Conditions
HIV
Interventions
HealthMPowerment App
Behavioral
Lead sponsor
Emory University
Other
Eligibility
14 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 1:50 AM EDT
Active, not recruiting Not applicable Interventional Results available

Early Protein Supplementation in Extremely Preterm Infants Fed Human Milk

NCT04325308
Site status not listed — check the official record
View directory record Official record
Conditions
Prematurity; Extreme, Feeding Disorder Neonatal, Breast Milk Expression, Growth Failure, Microbial Colonization
Interventions
Protein-enriched human milk diet, Usual human milk diet
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 4 Days
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 1:50 AM EDT
Not yet recruiting Not applicable Interventional

Pycnogenol (French Maritime Pine Bark) for the Treatment of Gulf War Illness

NCT07266571
Site status not listed — check the official record
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
Placebo, Pycnogenol, 100mg, Pycnogenol, 200mg, Pycnogenol, 400mg, Pycnogenol, 600mg
Other · Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 1:50 AM EDT
Recruiting Phase 2 Interventional

Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment

NCT06855433
Status at this site: Recruiting
View directory record Official record
Conditions
CPPD - Calcium Pyrophosphate Deposition Disease
Interventions
Colchicine Pill, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 1:50 AM EDT
Recruiting Not applicable Interventional

Responding With Evidence and Access for Childhood Headaches

NCT05889624
Status at this site: Recruiting
View directory record Official record
Conditions
Headache, Headache Disorders, Headache, Migraine, Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Chronic Migraine
Interventions
CBT, Amitriptyline
Behavioral · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 1:50 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study of Buntanetap in Participants With PD

NCT07284784
Status at this site: Recruiting
View directory record Official record
Conditions
Parkinson's Disease (PD), Deep Brain Stimulation
Interventions
buntanetap/posiphen
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
27
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 1:50 AM EDT

About this University of Alabama at Birmingham institution page

What this page lists
ClinicalTrials.gov records that list University of Alabama at Birmingham in Birmingham, AL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.